melphalan + misonidazole

Melphalan + misonidazole is an experimental combination therapy consisting of the alkylating agent melphalan and the nitroimidazole derivative misonidazole. Melphalan acts as a DNA cross-linking agent, leading to cytotoxicity in rapidly dividing tumor cells. Misonidazole is primarily known as a radiosensitizer but also functions as a chemosensitizer; it enhances the cytotoxic effect of melphalan, particularly in hypoxic tumor cells. The combination has been studied in preclinical models and early-phase clinical trials for its potential to increase antitumor efficacy by potentiating DNA damage and possibly altering drug pharmacokinetics or depleting intracellular thiols. This regimen has been investigated mainly for advanced solid tumors such as colorectal carcinoma and sarcoma[1][2][4].

Other names

melphalan and misonidazolemelphalan plus misonidazole